
Lysosomal Disorders
Latest News
Latest Videos

Podcasts
CME Content
More News

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending November 21, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

According to Intellia, the FDA placed clinical holds on both MAGNITUDE and MAGNITUDE-2 on October 29, 2025.

Review top news and interview highlights from the week ending November 7, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending October 31, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The patient showed grade 4 liver transaminases and increased total bilirubin and was hospitalized.

Review top news and interview highlights from the week ending October 24, 2025.

Deborah Phippard, PhD, and Renier Brentjens, MD, PhD, discussed their thoughts on major moments in the past 25 years of cell and gene therapy research.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending October 17, 2025.

The efficacy data included 4 patients who had discontinued their SOC therapy in a time frame of 4 to 11 weeks after being treated with FLT201.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA has set the PDUFA action date for the BLA at March 28, 2026.

With regard to safety, MYR-101 was characterized as “well tolerated” with a “favorable safety profile.”

Review top news and interview highlights from the week ending October 10, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending October 3, 2025.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive® team.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending September 26, 2025.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.



























































